Cladribine administration has been approved for the treatment of relapsing-remitting multiple sclerosis (MS) in 2017; thus, data on cladribine in a real-world setting are still emerging.
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study / Petracca, Maria; Ruggieri, Serena; Barbuti, Elena; Ianniello, Antonio; Fantozzi, Roberta; Maniscalco, Giorgia Teresa; Andreone, Vincenzo; Landi, Doriana; Marfia, Girolama Alessandra; Di Gregorio, Maria; Iodice, Rosa; Sinisi, Leonardo; Maida, Elisabetta; Missione, Rosanna; Coppola, Cinzia; Bonavita, Simona; Borriello, Giovanna; Centonze, Diego; Lus, Giacomo; Pozzilli, Carlo; Signoriello, Elisabetta. - In: NEUROLOGY AND THERAPY. - ISSN 2193-8253. - 11:3(2022), pp. 1193-1208. [10.1007/s40120-022-00364-6]
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study
Petracca, Maria;Ruggieri, Serena;Barbuti, Elena;Ianniello, Antonio;Borriello, Giovanna;Pozzilli, Carlo;
2022
Abstract
Cladribine administration has been approved for the treatment of relapsing-remitting multiple sclerosis (MS) in 2017; thus, data on cladribine in a real-world setting are still emerging.| File | Dimensione | Formato | |
|---|---|---|---|
|
s40120-022-00364-6.pdf
accesso aperto
Note: Petracca_Predictors of Cladribine Effectiveness_2022
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
646.65 kB
Formato
Adobe PDF
|
646.65 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
